


In the claims:

1. (Currently Amended) A compound of formula (I)



(I)

X is ~~CH₂ or SO₂~~

R¹ is an optionally substituted aryl;

R² is ~~carboxy, cyano, C(O)CH₂OH, CONHR⁸, SO₂NHR⁹, tetrazol-5-yl, or SO₃H~~

~~where R⁸ is selected from hydrogen, alkyl, aryl, cyano, hydroxy, SO₂R¹² where R¹² is alkyl, aryl, heteroaryl, or haloalkyl, or R⁸ is a group (CHR¹³)_rCOOH where r is an integer of 1-3 and each R¹³ group is independently selected from hydrogen or alkyl; R⁹ is hydrogen, alkyl, optionally substituted aryl such as optionally substituted phenyl or optionally substituted heteroaryl such as 5 or 6 membered heteroaryl groups, or a group COR¹⁴ where R¹⁴ is alkyl, aryl, heteroaryl or haloalkyl;~~


~~R³ is hydrogen, a functional group, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted alkoxy, optionally substituted aralkyl, optionally substituted aralkyloxy or optionally substituted cycloalkyl;~~

~~R⁴ is a group NHCOR¹⁵ or NHSO₂R¹⁵ where R¹⁵ is optionally substituted alkyl, or optionally substituted aryl or optionally substituted heteroaryl;~~

~~R⁵, R⁶ and R⁷ are independently selected from hydrogen, a functional group or an optionally substituted hydrocarbonyl group;~~

~~and further provided that when R⁴ is a group NHCOR¹⁵, R¹⁵ is substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl.~~

2. (Previously Presented) A compound according to claim 1 wherein a group R^{15} as it appears in the definition of R^4 , is substituted by at least one functional group, or an aryl or heterocyclyl group, either of which may themselves be substituted by one or more functional groups or further aryl or heterocyclyl groups.
3. (Previously Presented) A compound according to claim 1 wherein R^{15} is a substituted alkyl group or an optionally substituted heterocyclyl or optionally substituted phenyl group.
4. (Previously Presented) A compound according to claim 3 wherein R^{15} is alkyl substituted by a group of formula $NR^{19}R^{20}$ where R^{19} and R^{20} are independently selected from hydrogen or optionally substituted hydrocarbyl, or R^{19} and R^{20} together form an optionally substituted ring which optionally contains further heteroatoms such as $S(O)_m$, oxygen and nitrogen, n is an integer of 1 or 2, and m is 1 or 2.
5. (Previously Presented) A compound according to claim 1, where R^2 is carboxy.
6. (Previously Presented) A compound according to claim 1 wherein R^1 is 3,4-dichlorophenyl, 3-fluoro-4-chlorophenyl, 3-chloro-4-fluorophenyl or 2,3-dichloropyrid-5-yl.
7. (Previously Presented) A compound according to claim 1, where X is CH_2 .
8. (Currently Amended) A process for preparing a compound according to claim 1, which process comprises
reacting a compound of formula (VII)



(VII)

where X, R¹, R³, R⁵, R⁶ and R⁷ are as defined in claim 1, and R² is a group R² as defined in relation to formula (I) or a protected form thereof, with a compound of formula (VIII)



(VIII)

where Z is a leaving group and R²² is a group ~~COR^{15'}~~ or SO₂R^{15'} where R^{15'} is group R¹⁵ as defined in relation to formula (I) or a precursor thereof;

and thereafter if desired or necessary:

- (i) converting a precursor group R^{15'} to a group R¹⁵ and/or converting a group R¹⁵ to a different ~~such group R¹⁵~~; and
- (ii) deprotecting a group R^{2'} to a group R².

9. (Previously Presented) A pharmaceutical composition comprising a compound according to claim 1 in combination with a pharmaceutically acceptable carrier.

10. (Previously Presented) A method for antagonizing an MCP-1 (Monocyte Chemoattractant Protein-1) or RANTES (Regulated upon Activation, Normal T-cell Expressed and Secreted) mediated effect in a warm blooded animal in need of such treatment comprising administering to said animal an effective amount of a compound according to claim 1, a pharmaceutically acceptable salt, or an *in vivo* hydrolysable ester thereof.

11. (Previously Presented) A method for treating inflammation in a warm blooded animal in need of such treatment comprising administering to said animal an effective amount of a compound according to claim 1, a pharmaceutically acceptable salt, or an *in vivo* hydrolysable ester thereof.